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Objectives. Adherence to nebulizer treatment in adults with Cystic Fibrosis (CF) is
poor, and interventions are needed. This research aimed to identify the factors affecting
nebulizer adherence using the Theoretical Domains Framework (TDF) and to compare
these for participants with different levels of adherence.
Design. Data-prompted interviews using the TDF.
Methods. Eighteen semi-structured interviews were conducted with adults with CF
during which objectively measured adherence data were discussed. Framework
analysis was used to code the data into TDF domains, and inductive qualitative
content analysis was used to code different beliefs and experiences. Aspects of the
TDF that differed between participants with different adherence levels were
explored.
Results. Factors influencing adherence to treatment included all 14 domains of the TDF,
10 of which appeared to vary by adherence level: Skills; Memory and decision-making; and
Behavioural regulation; Environmental context and resources; Social influences; Beliefs
about consequences; Beliefs about capability; Reinforcement; Social role and identify;
Intentions; Optimism; and Emotions.
Conclusions. This study is the first to use objectively measured adherence data in a
data-prompted interview using the TDF framework to systematically assess the full
range of factors potentially influencing adherence. The results highlighted that
interventions need to consider issues of capability, opportunity, and motivation.
Interventions that challenge dysfunctional beliefs about adherence and which support
the development of routines or habits and problem-solving may be particularly useful
for adults with CF.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which
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modifications or adaptations are made.
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Statement of contribution
What is already known?
 Adherence to medication in adults with cystic fibrosis is poor.
 Previous research has identified a range of contributing factors in relation to subjective reports of
adherence.
 There is awide discrepancy between self-reported adherence andobjectivelymeasured adherence.
What this study adds
 A data-prompted interview using objectively measured adherence data enabled the systematic
assessment of potential factors that could be targeted in an intervention to increase adherence.
 There were some differences in the factors that were identified by high and low adherers.
 There is not one-size fits all intervention for adherence to medication in cystic fibrosis.
Cystic Fibrosis (CF) is a genetically inherited condition that affects approximately one
in every 2,500 babies born (Cystic Fibrosis Trust, 2019). CF causes the lungs and digestive
system to become clogged with thick sticky mucus (UK Cystic Fibrosis Registry Report,
2017) which results in recurrent lung infections, lung damage and ultimately, in over 80%
of cases, respiratory failure (O’Sullivan&Freedman, 2009). Themedian predicted survival
for a child born with CF is currently 47 years in the United Kingdom (UK Cystic Fibrosis
Registry Report, 2017).
Effective self-management of CF requires a complex daily regimen of treatment
(Sawicki, Sellers, & Robinson, 2009; Sawicki & Tiddens, 2012) including inhaled
treatments, usually delivered via a nebulizer; antibiotics to reduce infections, and
mucolytics (e.g., hypertonic saline and dornase alpha) to thin mucus and clear airways.
However, consistent with adherence rates across a range of long-term conditions,
adherence to nebulizer treatment in people with CF is low, ranging from 31% to 53% for
inhaled antibiotics and 53%–79% for inhaled mucolytics (Eakin, Bilderback, Boyle,
Mogayzel, & Riekert, 2011). Nebulizers such as I-neb (Philips Respironics) that
electronically record the time and frequency of nebulizations have shown a wide
discrepancy between patient self-reported adherence to inhaled therapy (80%) and
objective measurement of adherence (36%) (Daniels et al., 2011).
A range of qualitative studies, which havemainly used a thematic approach to analysis,
and reviews have attempted to understand the factors influencing adherence to treatment
in CF for adolescents and adults (Abbott, Havermans, & Hart, 2009; Arias-llorente, Garcıa,
&Martın, 2011; Foster et al., 2001; George et al., 2010; Hogan, Bonney, Brien, Karamy, &
Aslani, 2015; Hoo, Boote, Wildman, Campbell, & Gardner, 2017; Horky, Sherman, Laura,
Polvinen, & Rich, 2014; Lask, 1994; Macdonald et al., 2016; Pakhale et al., 2016; Sawicki,
Heller, Demars,&Robinson, 2015). Thesehave tended to find that adherence to treatment
is reported to be influenced by the extent of treatment burden, having the time to do
treatment, having a routine, forgetting to do treatment, a person’s identity, perceptions of
control, and social support. Knowledge and beliefs about the necessity of treatment, and
concerns about its effectiveness have also been commonly identified, consistent with the
Necessity–Concerns Framework that proposes that adherence to treatment occurswhere
necessity is perceived as high and concerns are low (Horne,Weinman, & Hankins, 1999).
While these studies provide some insights, they may not be accessing the full range of
factors that influence objectively measured adherence because subjective reports of
adherence are inaccurate (Daniels et al., 2011), and the factors affecting them may be
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subject to recall (Kimmel, Lewis, Jaskowiak, Kishel, & Hennessy, 2003) and social
desirability bias (Paulhus & Reid, 1991). Conversely, data-prompted interviews involve
using sources of objective data, such as graphical representations of quantitative data
(e.g., a graph showing objectively measured adherence), as a prompt for discussion in a
qualitative interview (Kwasnicka, Dombrowski, White, & Sniehotta, 2015) to reduce
problems of recall bias. The value of this methodology is that the data provide specific
examples of (non) adherence that can stimulate reflection (Harper, 2002), and the
relationships and any inconsistencies between thenarratives and the objective data canbe
explored in depth (Kwasnicka et al., 2015).
Psychological interventions have so far shown limited success in increasing
adherence in people with CF (Goldbeck, Fidika, Herle, & Quittner, 2014), and this
might be because the interventions are not targeting the most appropriate factors. For
example, Quinn et al. (2004) delivered a motivational interview intervention via
telephone to people with CF over a 3-month period but found no effect on adherence
rates compared to a control group.
Fully understanding the factors affecting adherence is an important step in the
process of developing effective evidence-based behaviour change interventions to
support self-management of long-term conditions. Such understanding enables the
design to be based on appropriate theories, and the components and effects to be
specified and empirically tested (Craig et al., 2015). There is evidence that interventions
based on theory are more effective than those that are not (Michie & Prestwich, 2010).
However, it can be difficult to identify which theories are most appropriate for a given
behaviour, population, and context. Focusing on one theory may result in some key
determinant(s) of the behaviour being missed (Patey, Islam, Francis, Bryson, &
Grimshaw, 2012).
The behaviour change wheel (BCW) provides a comprehensive framework for
intervention development established from a synthesis of other frameworks (Michie, Van
Stralen,&West, 2011;Michie, Atkins, &West, 2014) at the centre ofwhich sits the COM-B
model that proposes that behaviour (B) arises when an individual has sufficient capability
(C), opportunity (O), and motivation (M). The Theoretical Domains Framework (TDF;
Cane, Connor, & Michie, 2012) was developed using a systematic consensus approach to
identify and synthesize 14 key domains from 33 different behaviour change theories, each
of which describes a construct that influences capability, opportunity, or motivation
(Michie et al., 2011;Michie, Atkins, &West, 2014). TDF domains that influence capability
include the following: Knowledge (awareness); Skills (ability or competence); Memory,
attention, and decision processes (ability to retain information and to focus); and
Behavioural regulation (efforts to manage or change actions). Domains that influence
opportunities include the following: Environmental Context and Resources (aspects of a
person’s situation or environment that impacts on behaviour) and Social influences
(interpersonal influences that affect thoughts, feelings, or behaviours). Domains that
impact onmotivation include the following: Intentions (a decision to act in a certainway);
Goals (end states that an individual wants to achieve); Beliefs about Capabilities (self-
confidence and perceived behavioural control); Optimism (confidence that desired goals
will be attained); Beliefs about consequences (outcome expectancies); Reinforcement
(the response to a given stimulus – reward or punishment); Social/professional role and
identity (set of behaviours or qualities displayed in a social or work setting); and Emotion
(an individual’s reaction to amatter or event). The TDF is recommended as a framework to
inform interviews to identify the factors that influence a behaviour, within the BCW
framework for intervention development (Michie, Atkins, & West, 2014).
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The TDF has been used to identify factors relating to adherence to treatment for
bronchiectasis by patients and health care professionals (McCullough et al., 2015).
Presseau et al. (2017) conducted and coded interviews using the TDF and identified
Beliefs about consequences, Memory/Attention/Decision Processes, Behavioural Regu-
lation, Social influence, and Social/Professional Role and Identity as being domains
relevant tomedication adherence followingmyocardial infarction. However, no studies to
date have used the TDF to identify the factors affecting adherence in CF, and none have
utilized feedback from objective measures of behaviour to provide a stimulus for
discussion.
This study aimed to use the TDF to assess the factors affecting nebulizer adherence in
adults with CF to inform the development of an intervention. This is the first study to use
objective measures of adherence as a prompt to identify specific beliefs and experiences
related to adherence and to compare these beliefs and experiences in adultswith very low
adherence (0%–25%), low adherence (25.1%–50%), moderate adherence (50.1%–75%),
and high adherence (>75%).
Method
Semi-structured interviews were conducted with adults with CF who used an I-Neb
nebulizer to deliver antibiotic and/or mucolytic treatment. The I-Neb nebulizer
electronically recorded all treatments fromwhich data about date and time of nebulization
were downloaded and presented in graphical form (date, day, or time on the y-axis and
treatment taken on the x-axis). Interviewswere conducted by a researcher unknown to the
participants. During the interview, participants were shown charts of the last 6-month
adherence data including overall percentage adherence, time of day of administration, and
patterns of adherence across the days of the week. The charts were used as a prompt for
discussion about the specificbeliefs and experiences that affected their nebulizer treatment
adherence. The topic guide (available as a Appendix S1) comprised open questions about
the experience of adherence to treatment in CF (e.g., How easy or difficult is it to manage
your CF?) as well as specific questions about nebulizer adherence informed by the COM-B
and TDF (seeMichie et al., 2014; e.g., Do youhave the skills to be able to use your nebuliser
as prescribed?). Interviews were audio-recorded and transcribed verbatim.
Ethical approval for the study was obtained from [Hampshire A REC: 14/SC/1455].
Participants
Participants were selected from the 110 adults (16 years +) with CF who attended a CF
clinic in the United Kingdom and used at least one prescribed I-Neb treatment per day,
excluding thosewhowerepregnant, post-transplant, on the active transplant list, or in the
palliative phase of the disease. Selected participants were purposively sampled by age,
gender, socio-economic status (estimated from postcode using the English indices of
deprivation, 2015), and adherence rates (measured using the output from I-Neb devices
over the previous 6 months). Adherence rates were used to classify participants into
groups of very low adherers (VL: 0%–25%), low adherers (L: 25.1%–50%), moderate
adherers (M: 50.1%–75%), or high adherers (H: >75%). Participant characteristics are
summarized in Table 1. Age and adherence has been described in categories to prevent
the identification of participants, given the small population from which they were
sampled. Twenty-oneparticipantswere selected and invited to takepart in the study, from
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whom 20 consented, and 18 interviews were conducted (two participants were
unavailable to interview).
Analysis
Framework analysis was used to code the data (Ritchie & Spencer, 1994) using NVivo
(version 10, QSR International). SD read and coded the transcripts and selected parts of the
interview relating to nebulizer adherence which were analysed further. MA and SD
independently coded the selected sections using the 14 TDF domains as a framework.
Where text related strongly tomore than one TDF domain, itwas coded in both; otherwise,
it was coded under the domain that best matched the content. The coders met to discuss
and resolve any discrepancies and agree codes. The types of statements under each domain
were then analysed using inductive content analysis (i.e., identifying themes arising from
the data) to create sub-categories. The researchers met frequently to discuss and agree
coding and category descriptions which indicated common beliefs, experiences, and
perceived barriers and facilitators. Some categories were combined to form larger
categories that could be described under a single heading. Consistent with established
procedure (seeAtkins et al., 2017; Patey et al., 2012), categorieswere retained if reviewers
Table 1. Participant characteristics
Participant
number Gender
Age category
(years)
Types of
nebulized
treatments
taken (D, A, Ha)
Mean
adherence
categoryb
IMD deprivation
quintilec
1 M 19–25 D VL 4
2 M 16–18 D VL 3
3 F 31+ D, A VL 3
4 F 31+ D, A, H VL 4
5 F 26–30 D, A VL 5
6 F 16–18 D, A L 4
7 M 19–25 D, A L 5
8 M 19–25 D, A L 4
9 M 26–30 D, A L 4
10 M 26–30 D, A, H L 2
11 M 31+ D, A, H M 2
12 M 19–25 D, A M 3
13 M 31+ D, A, H M 4
14 M 16–18 D, A, H M 3
15 M 16–18 D, A H 2
16 F 31+ D, H H 3
17 M 31+ D, A H 2
18 M 19–25 D, A, H H 4
Notes. aD = dornase alpha (mucolytic), A = antibiotic: either a single antibiotic, or two antibiotics taken
in alternate months, H = hypertonic saline (mucolytic).
bWhere very low adherers (VL) = 0%–25% mean adherence, low adherers (L) = 25.1%–50% mean
adherence, moderate adherers (M) = 50.1%–75% mean adherence, and high adherers (H) = 75.1 + %
mean adherence.
cIMD deprivation quintiles: 1 ≤ 8.49 (Least deprived), 2: 8.5–13.79, 3: 13.8–21.35, 4: 21.36–34.17,
5: ≥34.18 (Most deprived).
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agreed the following: The belief statements were mentioned by several respondents; there
were conflicting beliefs, that is different participants reported opposing beliefs; or there
was evidence of strong beliefs that may affect the target behaviour.
The researchers looked for aspects of the TDF that differed between participants with
different adherence rates, such that belief categories were present in some adherence
levels but not others, and that the frequency of participants reporting category beliefs
between different adherence levels differed by two or more.
Results
Table 2 shows all 14 TDF domains and categories identified during analysis with example
quotes for themost frequently reported categories (for illustrative quotes in all categories,
see Table S1). Quotations are annotated with the participant number and their adherence
level (see Table 1).
Domains related to capability
All of the TDF domains1 related to capability featured strongly in the sample. The most
commonly reported category beliefs were as follows: struggling to plan treatment; having
knowledge about treatment-taking procedures; and having good nebulizer skills (see
Table 2). Some of the categories of belief differed between participants with different
levels of adherence (see Table 3).
Participants across all adherence groups reported having knowledge about their
nebulizer treatment, what it does, how and when to take it, and why it is important; and
the skills to do their nebulizer treatments, although there were a few specific difficulties
noted around sterilizing by boiling and opening containers. Sometimes knowledge about
the ‘rules’ of treatment taking were perceived to impact negatively on the ability to take
treatment: ‘. . .I couldn’t take one now and then take one at teatime because there’s only
4 hours between it and you’ve got to have 8 hours between it’ (P11: M). These ‘rules’
often reflected ideas about optimal treatment taking, and sometimes, treatment was
missed if it did not meet these rules.
Memory was identified such that some participants talked about forgetting their
nebulizer treatments, and this was mentioned by both very low and high adherers. More
commonly reported, particularly for very low, low, and moderate adherers, were
participants ignoring reminders to do their treatment: ‘I think, I’ve tried alarms in the past
and I tend to ignore those quite easily’ (P4: VL), suggesting that for some participants,
‘forgetting’ was a decision rather than an accident.
Participants spoke about using a wide range of behavioural regulation strategies.
Treatment plans or routines were widely discussed. Some participants identified specific
cues or prompts for treatment: ‘And you know I said about taking the DNase out of the
fridge at night-time and putting it next to the bed in the morning so I didn’t have to move
anywhere. It’s just there’. (P5: VL). Almost all participants talked about times and
situations in which they struggled to plan treatments or where routines were disrupted: ‘
we still struggle to get them all in to us on a daily basis . . . you know no matter, no matter
what we do there’s always sometimes a distraction or something happens like the
1 TDF domain names are italicised.
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Table 2. TDF domains and categories identified in relation to nebulizer adherence
COM factor TDF domain
Category – factors related to adherence to nebulized
treatment; n = number of participants reporting
category out of 18 participants
Illustrative quotes (see supplementary table for further
examples)
Capability
Knowledge  Having knowledge about treatment-taking procedures
(n = 16)
 Having knowledge about treatment action (how
treatments work) (n = 11)
 Having knowledge about the importance of nebulizer
treatment (n = 7)
 Having knowledge about treatment concerns (n = 3)
. . .you have to mix it up with like a liquid and then you have
got to dissolve it, shake it, wait for it to settle and then pop it
into the nebuliser (P10: L)
DNase which is the stuff that thins out the mucus to be able
to cough it up more easily. . . (P10: L)
Skills  Having good nebulizer skills (n = 14)
 Being able to concentrating on treatment taking
(n = 5)
 Not having preparation or cleaning skills (n = 3)
I can holdmy breath and I can do it exactly and I amone of the
shortest times to take it like it takes 1–3 min (P5: VL)
Like if I were going to have it now sort of . . . probably just,
not saying I couldn’t concentrate on other things but I just, I
couldn’t do it walking about (P18: H)
Memory, attention and
decision processes
 Ignoring reminders to take treatment (n = 9)
 Forgetting to take treatment (n = 7)
I think, I’ve tried alarms in the past and I tend to ignore those
quite easily. (P4: VL)
Get home later and it will completely slip mymind and I just
forget to do it all together. (P2: VL)
Behavioural regulation  Struggling to plan treatment (n = 17)
 Having a plan for treatment or having a routine
(n = 13)
 Knowing that others are monitoring nebulizer adher-
ence (n = 12)
 Create prompts or cues for treatment (n = 9)
we still struggle to get them all in to us on a daily basis . . .
there’s always sometimes a distraction or something
happens like the unexpected (P4: VL)
and sort of planning out when you’re going to take it and
things like that. . .that’s sort of themain thing forme (P12:M)
Continued
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Table 2. (Continued)
COM factor TDF domain
Category – factors related to adherence to nebulized
treatment; n = number of participants reporting
category out of 18 participants
Illustrative quotes (see supplementary table for further
examples)
 Self-monitoring nebulizer treatments (n = 6)
 Treatment is automatic or habitual (n = 5)
 Self-monitoring health outcomes/symptoms (n = 5)
 Planning rewards for yourself for good adherence
(n = 3)
They said at hospital it weren’t that bad but I, I, tome it were
bad. It were like 50%, probably less. . .(P8: L)
Opportunity
Environmental context and resources  Having the time or capacity to do treatment (n = 16)
 Having the equipment/resources for treatment taking
(n = 14)
 Weekends change the context for treatment (n = 13)
 Having an active social life as a barrier for treatment
(n = 11)
 Holidays and travel as barriers to treatment (n = 11)
 Being able and willing to take treatment away from
home or not (n = 11)
 The time of day can affect treatment (n = 10)
 Stressful or unusual events which are a barrier to
adherence (n = 6)
 Multi-tasking while doing treatment (n = 6)
 Hospital as a facilitator for treatment (n = 4)
 Distractions and interruptions to treatment (n = 4)
I’d say in themornings iswhen I just do the Promixin because I
haven’t got time to do anything else (P10: L)
That’s a pain. We were camping and it was really hard to
clean my neb properly. (P16: H)
I do it but the circumstances of doing it like effect like my
social life. . .(P7: M)
Social influences  Having support from family and others (n = 15)
 Having support from health care professionals (n = 11)
Me friend when [name] comes she’ll say ‘have you done your
nebulizers today?’ just in a general chat (P3: VL)
Continued
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Table 2. (Continued)
COM factor TDF domain
Category – factors related to adherence to nebulized
treatment; n = number of participants reporting
category out of 18 participants
Illustrative quotes (see supplementary table for further
examples)
 Making social comparisons with others who have CF
(n = 9)
 Experiencing conflict or nagging from others (n = 9)
 Being willing to take treatment in front of others or not
(n = 8)
 Perceiving a lack of or limited support (n = 5)
 Experiencing conflict with health professionals (n = 3)
 Declining offers of support or avoiding support from
others (n = 3)
As soon as they got it I went up t’hospital for a separate
appointmentwith one of physios and she taughtme through
it all. (P3: VL)
I think it’smore a case of as I say I know that’s there’s people
who takemoremedication and things thanwhat I do so (P9:
L)
Motivation
Social/Professional role and identity  Being organized or disorganized (n = 7)
 Being obstinate or rebellious (n = 7)
 Having control over treatment taking (n = 6)
 Being a lazy person or not (n = 5)
 Being the kind of person who takes their treatment
(n = 3)
. . .I’ve never really like planned things massively ahead so
yeah I don’t know. . . (P12: M)
if I’m really stubborn about it then the more nagging the
more it pushes me away. . . (P7: L)
Beliefs about Capabilities  Adherence to treatment is difficult (n = 16)
 Using a nebulizer is easy (n = 12)
 Adherence to treatment is easier with a routine
(n = 10)
 Nebulizer treatment is an annoyance (n = 10)
 Adherence to treatment is especially difficult when
tired (n = 7)
It’s not that hard just blowing through a machine for 5 min
before you go to bed, is it? (P18: H)
Its physicallymaking yourself do it . . .which is the thing (P7: L)
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Table 2. (Continued)
COM factor TDF domain
Category – factors related to adherence to nebulized
treatment; n = number of participants reporting
category out of 18 participants
Illustrative quotes (see supplementary table for further
examples)
Optimism  Believing that complete (100%) adherence is
unachievable (n = 8)
 Believing that complete (100%) adherence is achiev-
able (n = 5)
 Being uncertain about whether 100% adherence is
achievable (n = 4)
It’s just life. It’s never going to be absolutely hundred percent
is it? (P16: H)
It is though, it is because it is necessary and there is no
excuse not, so it is achievable 100%. . . because it’s
necessary cos it’s for your life (P14: M)
Beliefs about consequences  Nebulizer treatments are effective (n = 12)
 My health depends on me doing my nebulizer treat-
ment (n = 12)
 Nebulizer treatment are not (always) effective (n = 9)
 Nebulizer treatments help my symptoms (n = 9)
 Nebulizer treatment has long-term benefits (n = 7)
 Nebulizers are not the most important part of my CF
treatment (n = 6)
 Occasional non-adherence is OK (n = 6)
 Nebulizer treatment means I can avoid the need for
IVs/Hospital stays (n = 5)
 If I feel OK I don’t need to do my treatment (n = 5)
 Nebulizer treatments make me feel worse (n = 5)
 Bugs can become resistant to treatment (n = 3)
I do definitely think that all the nebulizer stuff is is a really
good a really good drug to to have and a necessary one I
think (P3: VL)
. . .as long as I do my treatment I know that in a few weeks’
time you know 95% of the time I’m absolutely fine I can do
whatever I like (P17: H)
So it’s like what’s the point in taking all this medication if
6 months down the line let’s say, it turns out that it’s really
done nothing, it’s been a waste of time (P2: VL)
Reinforcement  Feeling better as a result of nebulizer treatment
(n = 11)
 Not feeling that the nebulizer is working (n = 10)
 Experiencing negative effects of the nebulizer treat-
ment (n = 8)
After a couple of days of being on it, I will cough more up, it
does feel a lot thinner and my lungs feel clearer (P13: M)
well you don’t straight away but say you have like aweek off,
youwill feel awful and your chestwill hurt all the time (P6: L)
Continued
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Table 2. (Continued)
COM factor TDF domain
Category – factors related to adherence to nebulized
treatment; n = number of participants reporting
category out of 18 participants
Illustrative quotes (see supplementary table for further
examples)
 Experiencing other rewards for adherence to treat-
ment (e.g., improvements in lung function or praise
from clinicians) (n = 5)
 Feeling worse as a result of not doing nebulizer
treatment (n = 4)
 Experiencing negative consequences of non-adher-
ence to treatment (n = 4)
DNase doesn’t – I don’t even notice any difference. I don’t
know if it does anything or not (P16: H)
Intention  Having an unstable intention for adherence or non-
adherence (only some of the time) (n = 14)
 Having a stable intention for adherence or non-
adherence (n = 13)
 Intending to change (improve) adherence (n = 11)
I do do it, whatever time I come in, and again, even if I’m
drunk, which is very rare! (P16: H)
maybe if I’m sort of going round there to someone’s house
and I’m staying one night, I’ll maybe say ‘well I’ll miss the
night dose and I’ll miss the morning dose’ (P13: M)
Goals  Having other life goals (n = 14)
 Having goals for the amount of treatment taken
(n = 13)
 Having goals related to health outcomes (n = 13)
 Having goals that conflict with the ability to take
treatment (n = 12)
 Not having or avoiding goals (n = 12)
I think that having kids makes me think that I don’t wanna be
ill. . . cos I have to be alive for them and well for them. . .
(P16: H)
Like if this time next year, if you can tell me it’s still ninety
five percent, I would be happy. You know what I mean?
(P18: H)
Emotion  Experiencing low mood or depression (n = 8)
 Feeling regret or anticipating feeling regret (n = 5)
 Feeling fearful (n = 4)
 Avoiding thinking about CF or treatment (n = 4)
But now I mean I am trying to take it every morning but it’s
just yeah I think a lot of my medication at the minute is
actually depression related why I can’t take it (P5: VL)
Because then because if I do get to that stage, which I’ve kind
of accepted [I] am. . . I can, I can’t look back and say I could
have done better. (P15: H)
A
dherence
and
the
T
D
F
1
1
unexpected’ (P4: VL). Lower adherers but not moderate or higher adherers reported
planning rewards for themselves for adherence to treatment.
Some, mostly moderate or high adherers talked about some aspects of their treatment
being automatic or habitual and requiring less effort: ‘ It definitely is a routinemindset . . . I
don’t even think about it in the morning particularly, if I’m going to work. . .’ (P17: H).
Participants talked about self-monitoring their treatment taking by looking at the
battery level on the nebulizer or the amount of medications used, andmostly moderate to
high adherers talked about self-monitoring their health (e.g., lung function) or CF
symptoms (e.g., coughing). Most participants spoke, and were positive about, health
professionals monitoring their treatment using downloads from their I-Neb nebulizer:
‘It’s nice to have the feedback’. (P7: M).
Domains related to opportunity
Both of the TDF domains related to opportunity featured in the sample. The most
commonly reported category beliefs were as follows: having the time or capacity to do
treatment; having support from family or others; and having the equipment/resources for
treatment taking (see Table 2). A proportion of the categories of belief differed between
participants with different levels of adherence (see Table 4).
Environmental contexts relevant for adherence included temporal factors, locations,
events, resources, and competing demands. A majority of environmental categories were
identified by participants across the range of adherence categories. Some factors were
consistently perceived as barriers including social life, holidays, and travel. Some
participants found taking treatment away from homewas not a barrier while others were
unwilling to do so.
Some environmental factors were experienced differently across adherence cate-
gories. Very low adherers reported that being in hospital was a facilitator for treatment: ‘I
do it in hospital, come out, do it for about a week or so, and then after that, I’m back to
Table 3. TDF domains associated with capability where there are different patterns of category beliefs
between participants with different levels of adherence
TDF domain Category
Adherence level
V low
(n = 5)
Low
(n = 5)
Mod
(n = 4)
High
(n = 4)
Skills Not having preparation
or cleaning skills
0 1/5 0 2/4
Memory,
attention,
and decision
processes
Forgetting to take
treatment
3/5 0 1/4 3/4
Ignoring reminders
to take treatment
3/5 4/5 2/4 0
Behavioural
regulation
Treatment is automatic
or habitual
0 2/5 0 3/4
Self-monitoring health
outcomes/symptoms
0 2/5 1/4 2/4
Planning rewards for
yourself for good adherence
1/5 2/5 0 0
Note. Light shading indicates <50% of participants; dark shading indicates ≥50% of participants.
12 Madelynne A. Arden et al.
where I were. . ..’ (P2:VL). Stressful or infrequent events (e.g., Christmas, moving house)
were barriers for treatment for participants with low andmoderate adherence but not for
high adherers.
Some participants reported that they were able to engage in other tasks while doing
treatment; however, for mostly high adherers, distractions were a barrier to treatment:
‘Sometimes, I don’t finish, you knowwhen you start it, I then get busywith kids and don’t
finish, then I have to start it again’. (P16:H)
Social influences included support from others, the impact of social situations on
treatment, conflict with others, and social comparison. Willingness to take treatment in
front of others was not necessarily a barrier to adherence given that most high adherers
were not willing.
Almost all participants except the two lowest adherers spoke about the social
support that they received from at least one source: from family, health care
professionals, and others: ‘I don’t think I’d do it, if I didn’t have the motivation to get
out my bed I wouldn’t do it, if [my mother] didn’t bring it upstairs’ (P6: M), although
some participants reported receiving limited support, and some lower adherers
reported declining or avoiding support-seeking: ‘I don’t like offloading stuff like that I
don’t like [my partner]doing it but that’s just me’ (P3: VL). A number of participants
reported that their adherence (or lack of) caused conflict with others, both family and
health professionals. Notably, it was only very low adherers who reported conflict
with health professionals, for example: ‘he were basically telling me off. . . in front of
a load of other people . . .’. (P3: VL)
Table 4. TDF domains associatedwith opportunitywhere there are different patterns of category beliefs
between participants with different levels of adherence
TDF domain Category
Adherence level
V low
(n = 5)
Low
(n = 5)
Mod
(n = 4)
High
(n = 4)
Environmental
context and
resources
Times of day help with
treatment
0 2/5 2/4 2/4
Stressful or usual events
are a barrier to treatment
3/5 2/5 1/4 0
Hospital is a facilitator
for treatment
3/5 1/5 0 0
Distractions and
interruptions are
a barrier
1/5 0 0 3/4
Social influences Conflict with health
professionals
3/5 0 0 0
Declining/avoiding
support from others
2/5 1/5 0 0
Willing to take treatment
in front of others
1/5 0 1/4 1/4
Not willing to take
treatment in front
of others
1/5 2/5 0 3/4
Note. Light shading indicates <50% of participants; dark shading indicates ≥50% of participants.
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Participants across all adherence categoriesmade social comparisonswith otherswith
CF in terms of how much treatment they needed to take, how they managed their
adherence, factors affecting their ability to adhere, and the impact of this on their health.
Domains related to motivation
All of the TDF domains related to motivation featured in the sample. The most commonly
reported categories were as follows: that adherence to treatment is difficult; having other
life goals; and having unstable intentions for adherence or non-adherence (see Table 2). A
large proportion of the categories of belief differed between participants with different
levels of adherence (see Table 5).
Participants talked about a range of personal qualities and social identities that
influenced their adherence to nebulizer treatment in either positive or negative ways.
Some of these qualitieswere perceived to be stable and consistent since childhood, or as a
result of parental influence. Participants with higher adherence used different identity
constructions (the kind of person who takes their treatment; being organized) while
lower adherers talked about being obstinate or rebellious, or being ‘lazy’ or disorganized:
‘And you can’t turn stubborn off, you can’t, if you’re a stubborn person you’re a stubborn
person for life’. (P2: VL)
Almost all participants believed that theywere capable such that nebulizer treatments
were quick and easy to do, although most participants found them or the processes
around them to be an annoyance, particularly cleaning and sterilizing nebulizers. Across
all adherence groups, participants reported that adhering to nebulizer treatment was
difficult. Specifically, tirednesswas perceived tomake adherencemore difficult (although
not for high adherers) and having a routine was perceived to make adherence easier: ‘On
the whole I’d say it’s alright like majority of the time I feel like I manage it quite well but I
think that sometimes I don’t know I thinkmore recently I’ve noticed it that like if I get out
of a routine then it becomes difficult to manage. . .’ (P12: M).
Participants with lower adherence tended to report being optimistic that 100%
adherence was possible, while those with higher adherence reported being more
pessimistic: ‘It’s just life. It’s never going to be absolutely hundred percent is it?’ (P18: H)
Participants discussed a wide range of necessity and concern beliefs about nebulizer
treatments and the consequences of adherence and non-adherence. Across all adherence
categories, participants reported that nebulizer treatments are effective, help with
symptoms, are important to be able to remain well/avoid becoming ill, avoid the need for
hospital stays, and have long-term benefits. Within this belief and across adherence
categories, there was also an understanding that occasional non-adherence was
acceptable to some.
Participants across all adherence categories believed that nebulizer treatments were
not always effective although the extent of this lack of effectiveness varied, so that very
low adherers believed that theymay not be effective at all: ‘a waste of time’ (P2: VL) while
higher adherers thought that there were some types of treatment that were not fully
effective: ‘. . .because that is helping my chest, this keeps certain infections at bay, but
every now and then one will creep through’ (P14: M).
Participants’ beliefs that nebulizers were not the most important part of CF treatment
occurred across adherence categories. Some participants believed that IV antibiotic
treatments (P1: VL, P5: VL, P9: L, P18:H) physiotherapy (P6:L) and exercise (P6: L; P17:H)
were more important than nebulizers. The belief that treatment was not needed if
participants felt well was held by low and very low adherers.
14 Madelynne A. Arden et al.
Table 5. TDF domains associated with motivation where there are different patterns of category beliefs between participants with different levels of adherence
TDF domain Category
Adherence level
V low
(n = 5)
Low
(n = 5)
Mod
(n = 4)
High
(n = 4)
Social role and identity Being the kind of person who takes their treatment 0 1/5 0 2/4
Being lazy 1/5 2/5 1/4 0
Not being lazy 0 0 0 1/4
Being organized 0 1/5 0 2/4
Being disorganized 2/5 0 2/4 0
Being obstinate or rebellious 4/5 2/5 1/4 0
Beliefs about capability Especially difficult when tired 1/5 4/5 2/4 0
Optimism Complete adherence is achievable 2/5 1/5 2/4 0
Complete adherence in unachievable 0 3/5 2/4 3/4
Uncertain about whether adherence is achievable 2/5 0 2/4 0
Beliefs about consequences Nebulizers are not the most important part of my CF treatment 2/5 3/5 0 3/4
Nebulizer treatments make me feel worse 3/5 1/5 1/4 0
Bugs can become resistant to treatment 0 0 2/4 1/4
Reinforcement Feeling worse as a result of not doing nebulizer treatment 1/5 2/5 0 1/4
Other rewards for adherence to treatment 2/5 0 0 3/4
Intentions Having stable intentions not to adhere 2/5 2/5 0 0
Having unstable intention to adhere 3/5 4/5 2/4 0
Emotions Feeling regret or anticipated regret 1/5 1/5 0 3/4
Feeling fearful 0 1/5 0 3/4
Avoiding thinking about CF or treatment 2/5 1/5 0 0
Note. Light shading indicates <50% of participants; dark shading indicates ≥50% of participants.
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Some participants in the very low and low adherence categories reported that their
nebulizer treatment made them feel worse, often due to reported side effects. Some
participants in the medium and high adherence categories reported beliefs about
treatment resistance: ‘I was told that [the bacteria] actually become acclimatised to it, and
it would lose its effectiveness’ (P13: M)
Participant’s beliefs about reinforcement from treatment varied in part because of
the different drugs that they were taking. Hypertonic saline (a mucolytic) was reported
to have immediate noticeable effects on coughing and sputum levels: ‘Yeah. Always do
hypertonic saline first with salt water, so that makes me cough like mad, and that will
get the easy stuff up as it were’ (P13: M). Antibiotic treatments were perceived as the
least likely to produce noticeable effects: ‘Stuff that I’ve had like all my life, like
Colomycin. It’s like just an antibiotic that you take. My chest feels exactly the same
whether I’m on that or not. And then some of the nebulisers and antibiotics, I’ve started
on. . . I don’t feel any different if I’m taking them or not’. (P18:H). Some participants had
experienced negative effects of their treatments which included the following: feeling
tight chested, wheezy, coughing, losing their voice, itching, ‘the shakes’, and unpleasant
smell or taste.
Some participants spoke about receiving reinforcement from others for their
adherence including receiving praise for efforts to adhere (lower adherers): ‘I get enough
praise when I go up to the hospital. It actually is really helping seeing the physios every
two weeks’. (P5: VL); or very high levels of adherence or lung function (high adherers):
‘When the physio printed out my nebuliser thing at my annual review a couple of years
ago, she was like, Whoa! 98% compliance! Can I show this to other people!’ (P16: H).
Reinforcement could also be through a negative outcome, for example being ‘told off’
for low adherence. This was more commonly reported by low–very low adherers but one
high adherer (P15:H) also described a past experience that prompted an improvement in
their adherence: ‘. . .And that’s when it really kicked in when I saw my lung deteriorating
and it were like I can do a lot more than what I have been doing. That’s what really did it.
Ever since then I would say I have been between 80-90%’ (P15: H)
Patterns of intention between high and low adhererswere difficult to discern because
participants talked about different periods of adherence at different times. However, only
low adherers reported stable intentions for non-adherence. Many participants, like P15
above, reported moments where they made a conscious decision to change, that is to
increase their adherence or ‘getting back on track. . .’(P14: M).
Most participants across all adherence groups reported occasional periods of
intentional non-adherence. For some, there were particular occasions when treatment
would be intentionally missed. While for others, intentional non-adherence was for some
but not all daily prescribed treatments: ‘. . .and I was supposed to take it 4 times a day.
Even, when I were proper on it I’d only take it 3 times a day’ (P11: M)
Participants reportedhaving awide variety of goals related to adherence for treatment,
their health, and their life generally, although some reported avoiding having goals. Those
with low adherence tended to talk about more modest treatment goals: ‘we are working
on me trying to do the night time ones’. (P3: VL) while high adherers’ treatment goals
appeared more ambitious: ‘Just take them all’. (P18: H).
Life goals were varied and included being well enough to go on holidays, get married,
have and bring up children, and employment goals. Some goals were in conflict with
adherence and included the following: wanting to be normal/have a normal life, family, or
child-related goals, work and school goals, goals related to other treatments, social life and
friends, and relaxation and sleep.
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Participants expressed emotions in relation to how they felt about treatment
adherence in relation to havingCF and in terms of emotional factors that impacted on their
ability to adhere. Participants expressed regret that they had experienced in relation to
non-adherence, and about adherence as a way to avoid anticipated regret: ‘because then
because if I do get to that stage, which I’ve kind of accepted [I] am. . . I can, I can’t look
back and say I could have done better’. (P15: H). Fear was perceived to be a driver for
adherence, particularly for the highest adherers: ‘Yeah, I’m a good girl, cos I’m terrified,
I’m terrified of being ill. . .’ (P16: H). Conversely, some lower adherers, avoided thinking
about CF and adherence: ‘I find other things to do, like to put me off it, like put it to the
back of my mind. If I don’t think about it, I ain’t got to do it sort of thing’ (P2:VL).
Low mood was often used to explain periods of lower adherence; ‘It all depends on
what kinda day I’ve had and how I feel on that day. . .’ (P3:VL) but this did not vary by
adherence level. Sometimes lower adherence was in relation to day to day fluctuations in
mood, periods of stress that resulted in low mood, or longer periods of depression.
Discussion
This study aimed to use the TDF to assess the factors affecting nebulizer adherence in
adults with CF to inform the development of an intervention. The TDF allowed for a
thorough and systematic assessment of the factors influencing adherence in this sample of
adultswith theCF. Using objectivelymeasured adherence data as a stimulus for discussion
enabled a more thorough and realistic discussion of the beliefs and experiences affecting
adherence (Kwasnicka et al., 2015). All of the 14 TDF domains showed some variation
across individuals, consistent with the view that a one-size fits all intervention is unlikely
to be successful (Easthall & Barnett, 2017). Ten TDF domains showed apparent variation
across adherence levels and might be particular targets for intervention (Skills; Memory,
attentions and decision processes; Behavioural regulation; Environmental context and
resources; Social influences; Social role and identify; Beliefs about capability; Optimism;
Beliefs about consequences; Reinforcement; Intentions; and Emotions). These domains
and the specific beliefs categories provide a basis for the next steps of intervention
development using the BCW (Michie et al., 2011).
Having access to objectively measured adherence data for each participant allowed us
tomake some tentative comparisons between higher and lower adherence in terms of the
domains and belief categories that were reported to influence their nebulizer adherence.
Many of the domains identified in this study as being relevant have been identified in
previous qualitative studies (Macdonald et al., 2016; Sawicki et al., 2015). However, the
objectively measured adherence data for the participants enabled greater insight about
which of these factors might explain differences in adherence levels, and therefore, what
might be the best factors to focus on in an intervention, as well as those that may be
inappropriate.
Knowledge about treatment has regularly been identified as a theme in qualitative
studies (Sawicki et al., 2015). However, consistent with studies showing no relationship
between knowledge and adherence (Lin, Kendrick, Wilcox, & Quon, 2017; Modi &
Quittner, 2006), this study shows that most participants report that they have good levels
of knowledge. This is consistent with a systematic review that showed that knowledge is
necessary but not sufficient to promote medication adherence (Kahwati et al., 2016).
Likewise, having the time/capacity to do treatment was identified which is consistent
with qualitative work identifying the importance of this factor (Sawicki et al., 2015).
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However, time was identified as important by both high and low adherers, and yet high
adherers were able to overcome this challenge suggesting that there are other
motivational or capability issues (see Michie et al., 2011) that are more likely to explain
adherence differences and hence be suitable targets for intervention.
Consistentwith the necessities and concernsmodel (Horne et al., 1999), and previous
research into adherence in CF (e.g., Sawicki et al., 2015), participants reported a wide
range of different beliefs about the consequences of nebulizer adherence/non-adherence.
Participants did not get direct positive reinforcement from most of their nebulized
treatment, and this could lead to participants to question its effectiveness. Given the range
of different beliefs expressed across different categories of adherence, interventions
should seek to address specific dysfunctional beliefs relevant to the individual. This
approach has been used successfully in an intervention to improvemedication adherence
in stroke survivors (O’Carroll, Chambers, Dennis, Sudlow, & Johnston, 2013).
Lower adherers in this study were more likely to report ignoring reminders to take
their treatment. This ‘purposeful forgetting’ (George et al., 2010) is consistent with the
findings of a large randomized controlled trial which showed no effect of reminders on
adherence (Choudhry et al., 2017). Reminders are only likely to be effective (and serve to
prevent ‘forgetting’) if the recipient has a strong intention to adhere. The finding that
lower adherers reported intentional non-adherence highlights the need for interventions
to increase motivation for those individuals.
Participants across the board reported that, at least on occasion, they struggled to
plan to take nebulizers and most highlighted the importance of routines in being able
to adhere. Action planning (Sniehotta, Schwarzer, Scholz, & Sch€uz, 2005) is therefore
likely to be an important component and has been used successfully in interventions to
increase adherence to medication in other conditions (de Bruin et al., 2017; O’Carroll
et al., 2013).
The highest adherers commonly reported that they did their treatments automatically,
indicating that it was habitual. This is consistent with recent research showing the
importanceof automaticmotivationhabits in adherence (Hoo et al., 2019; Phillips, Cohen,
Burns, Abrams, & Renninger, 2016), including evidence that adherence interventions that
focus on habit formation are the most effective (Conn & Ruppar, 2017). Habits mean that
adherence requires less cognitive effort (Gardner, de Bruijn, & Lally, 2011), and thismeans
that habits can be maintained in circumstances that might make treatment taking more
challenging (Gardner, 2015). This could explainwhy itwasmostly low–moderate adherers
and not high adherers that reported that stressful events were a barrier to adherence.
People with strong habits may be able to take their treatment even in the context of
stressful life events. Alternatively, experiencing stressful life events may lead to chaotic
unpredictable lifestyles which have been found to be associated with lower adherence
(Wong, Sarkisian, Davis, Kinsler, & Cunningham, 2007; Zullig et al., 2013).
In addition to stressful events, participants reported a wide range of environmental
factors which impacted on their ability to adhere. Being able to plan how to overcome
these barriers or ‘coping planning’ (Sniehotta et al., 2005) is also likely to be an important
part of a successful intervention to improve adherence (de Bruin et al., 2017).
Most high adherers reported experiencing fear as a factor that affected their adherence
as has been reported previously (White, Miller, Smith, & McMahon, 2009). Conversely
lower adherers reported avoidance consistent with previous research (Abbott, Dodd,
Gee, &Webb, 2001). These emotionsmay reflect alternate responses to the perception of
threat. Protectionmotivation theory (Rogers, 1975, 1983) suggests that a perceived threat
is likely to result in fear (threat appraisal) that can be reduced either by behavioural action
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(adherence) where individuals have the resources (i.e., capability and opportunity) to act
(coping appraisal), or by avoidance where individuals lack those resources. Interventions
should therefore focus on increasing the individual’s capability and opportunity to act and
to increase their confidence that they can cope.
Implications for interventions and clinical practice
This study illustrates thewide rangeof factors affecting nebulizer adherence in adultswith
CF and emphasizes that different people have different issues affecting their adherence
including issues ofmotivation, capability, and opportunity. There is not therefore a simple
one-size fits all intervention that can be effective and clinicians need to be aware of these
differences in order to tailor adherence support appropriately.
This study also highlights the importance of clinician access to objectively measured
adherence data to inform discussions about adherence since time and date stamped data
enable respondents to identify beliefs and experiences related to specific instances of
documented behaviour. Concerns are often expressed about the use of objective
adherence datawithin consultations because of fears of ‘big brotherwatching’ (Campbell,
Eyal, Musiimenta, & Haberer, 2016); however, participants in this study were aware that
health professionals were monitoring their adherence as part of their care and were
positive about the role that this played in helping them to understand and support their
adherence.
The role of health professionals was highlighted in a number of categories. Having
social support from health professionals was identified as important but lower adherers
were more likely to report conflict with health professionals. It may be that conflict had
arisen as a result of low adherence, for example where health professionals have tried to
impress, perhaps a little too forcefully, the importance of adherence. Or it could be that
conflict with health professionals results in a lack of trust which results in lower
adherence. In a complex disease such as CF, the relationship between patient and health
professional is extremely important and should allow for good communication and
mutual respect (Arias-llorente et al., 2011; Sawicki et al., 2015); thus, communication
style is an important consideration in practice and intervention development (Hagger &
Hardcastle, 2014).
Strengths and limitations
This research enabled us to identify a wide range of beliefs and experiences about
nebulizer adherence in adults with CF and to begin to understand how these beliefs might
be related to objectively measured nebulizer adherence. This understanding enabled the
identification of potential factors from the TDF to address in an intervention, across issues
of capability, opportunity, and motivation.
Previous studies that have used the TDF approach have tended to identify fewer
domains as being relevant for adherence (McCullough et al., 2015; Presseau et al., 2017).
Our greater yield might be the result of using objective adherence as a stimulus during the
interviewor that the investigators recognizedmore conflicting beliefs (Atkins et al., 2017;
Patey et al., 2012) due to comparing participants with different adherence levels. The
interview schedule also included prompts that related to TDF domains (as recommended
byMichie et al., 2014), and this may have resulted in participants commenting on awider
range of domains than theywould have donewithout these prompts. However, our ability
to use objective adherence data to interpret the potential importance of the domains has
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enabled us to narrow down the category beliefs that might be particularly relevant for
intervention development.
This research has a number of limitations. First, therewere a relatively small number of
purposively sampled participants interviewed and the comparisons made between
participants with different categories of adherence must be tentative as a result. Future
research should utilize a larger sample powered to detect a difference. Second, the sample
is context specific and drawn from a single CF centre in the United Kingdom. There must
be some caution in transferability of findings to CF outside this context and to other
conditions (Morse, 2015). While the participants were purposively sampled to represent
the range of characteristics of adults with CF, they were only sampled from the 110
patients who were willing to use an I-Neb that enabled the tracking of treatment taking,
and it is conceivable that the clinic practices, particularly the regular downloading and
discussion of I-Neb data, influenced the findings to some extent. Future research should
explore the extent to which these findings are generalizable. Third, although we have
identified some potentially important factors to target in an intervention, it is not possible
from these data to determine how these factors might interact to influence adherence.
Conclusion
This research study is the first to use objectively measured adherence data in a data-
prompted interview using the TDF framework. This technique enabled the systematic
assessment of participants’ adherence-related beliefs and experiences and enabled
comparisons between participants with different levels of adherence. The analysis
enabled the identification of TDF factors related to capability (i.e., Skills; Memory and
decision-making; and Behavioural regulation), opportunity (i.e., Environmental context
and resources; and Social influences), and motivation (i.e., Beliefs about consequences;
Beliefs about capability; Reinforcement; Social role and identify; Intentions; Optimism;
and Emotions) that likely need to change in order to support adherence to nebulizer
treatment, although there is unlikely to be a one-size fits all solution. These findings can be
used to develop suitable interventions using the BCW (Michie et al., 2014).
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